RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.

导出 OA

翻译打印收藏纠错

第一作者： Xi,Yuan

第一单位： Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., China.

作者： Xi,Yuan ^[1] ; Zhiyu,Tang ^[2] ; Rong,Du ^[1] ; Zhan,Yao ^[3] ; Shing-Hu,Cheung ^[1] ; Xinwen,Zhang ^[1] ; Jing,Wei ^[1] ; Yuan,Zhao ^[1] ; Yunguang,Du ^[4] ; Ye,Liu ^[4] ; Xiaoxia,Hu ^[2] ; Wenfeng,Gong ^[2] ; Yong,Liu ^[2] ; Yajuan,Gao ^[2] ; Zhiyue,Huang ^[5] ; Zongfu,Cao ^[2] ; Min,Wei ^[4] ; Changyou,Zhou ^[6] ; Lai,Wang ^[2] ; Neal,Rosen ^[3] ; Paul D,Smith ^[7] ; Lusong,Luo ^[8]

作者单位： Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., China. ^[1] Department of Pharmacology, BeiGene (Beijing) Co., Ltd., China. ^[2] Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[3] Department of Biochemistry, BeiGene (Beijing) Co., Ltd., China. ^[4] Global Statistics and Data Science, BeiGene (Shanghai) Co., Ltd., China. ^[5] Department of Chemistry, BeiGene (Beijing) Co., Ltd., China. ^[6] AstraZeneca, CRUK Cambridge Institute, Robinson Way, UK. ^[7] External Innovation, BeiGene, Ltd., San Mateo, CA, USA. ^[8]

关键词 MEK inhibitor RAF dimer inhibitor RAS-mutated cancer combination therapy synergy